Pfizer Inc. (NYSE:PFE) Stock Holdings Boosted by Optimist Retirement Group LLC

Optimist Retirement Group LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 198.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 83,937 shares of the biopharmaceutical company's stock after purchasing an additional 55,823 shares during the period. Optimist Retirement Group LLC's holdings in Pfizer were worth $2,127,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. acquired a new stake in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC lifted its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. North Capital Inc. bought a new position in Pfizer in the first quarter worth about $28,000. Bernard Wealth Management Corp. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $30,000. Finally, Horizon Financial Services LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Morgan Stanley increased their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Redburn Atlantic decreased their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $28.55.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.29 during trading on Wednesday, reaching $25.43. The stock had a trading volume of 22,439,667 shares, compared to its average volume of 41,861,649. The business has a fifty day moving average price of $24.07 and a 200-day moving average price of $24.71. The stock has a market cap of $144.55 billion, a PE ratio of 18.42, a PEG ratio of 0.88 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the business earned $0.82 EPS. Pfizer's revenue was down 7.8% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.